The Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) trial showed that the benefit of clopidogrel in patients with an acute minor stroke or a high-risk TIA in China depends on their CYP2C19 genotype and their ESRS score. Here, CYP2C19 is linked to transient ischemic attack.